# bpc157dr.com # BPC-157 Dr. — Independent research summary on Body Protection Compound 157 > Plain-language summary of the BPC-157 (Body Protection Compound 157) research literature: mechanism, animal studies, pharmacokinetics, three published human reports, and regulatory status. A fifteen-amino-acid peptide. Thirty-plus years of rodent studies. Three small human reports. One regulatory file marked Category 2. Here is what the literature actually says. ## § 00 The short version BPC-157 is a synthetic fifteen-amino-acid peptide derived from a protein found in human gastric juice. It is studied for tissue repair across tendons, muscle, bone, gut and the nervous system — all in rodent models. Thirty-plus years of animal work describes consistent repair effects at multiple levels of biology. The human data are a different story: three small, uncontrolled reports from a single investigator group, none of them a randomized controlled trial. The FDA placed BPC-157 on its Category 2 list in 2023, excluding it from pharmacy compounding. WADA prohibits it in sport. No regulatory body has approved it for any human indication. That is the complete official evidence picture. For what people report using it — benefits and adverse effects — see [the effects page](/effects). ## § 01 The compound BPC-157 is a synthetic peptide of fifteen amino acids — the sequence GEPPPGKPADDAGLV — drawn from a larger cytoprotective protein found in human gastric juice [11]. It is also catalogued as Pentadecapeptide BPC 157, PL 14736, PL-10, and PLD-116. Its molecular weight is 1419.55 Da. Its CAS number is 137525-51-0. Its defining structural feature is three consecutive prolines at positions 3, 4, and 5, which appears to confer resistance to gastric proteolysis and allows researchers to administer it in drinking water in many rodent studies [11]. This site is a reading of the literature. It is not a clinic. It does not prescribe, dispense, or recommend. ## § 02 What the studies describe Across more than three decades of preclinical work, BPC-157 has been studied as a multi-pathway cytoprotectant. Reports describe modulation of the nitric oxide system through endothelial nitric oxide synthase (eNOS), promotion of angiogenesis through the VEGFR2-PI3K-Akt-eNOS pathway, and engagement of ERK1/2 MAPK and FAK-paxillin signaling relevant to fibroblast migration and collagen organization [4][20]. In transected rat Achilles tendons, BPC-157 at 10 μg/kg or 10 ng/kg intraperitoneal increased load-to-failure, improved collagen and reticulin organization, and restored macroscopic tendon integrity [1]. In rabbit segmental bone defects, 10 μg/kg produced bony union comparable to autologous cortical bone grafting [5]. In a 2025 rat model of surgically detached quadriceps muscle, per-oral BPC-157 in drinking water closed the muscle-bone gap by day 21-28 and restored walking pattern [14]. In gastrointestinal models, the peptide is reported to reduce anastomotic leakage and increase burst pressures across esophagogastric, colocolonic, jejunoileal, and ileoileal segments in rats [13], and to close colocutaneous, duodenocolic, and tracheocutaneous fistulas [7][19][23]. ## § 03 Pharmacokinetics He et al. (2022) profiled BPC-157 in Sprague-Dawley rats and beagle dogs after intramuscular dosing. Intramuscular bioavailability was 14-19% in rats and 45-51% in dogs. Tmax was approximately 3 minutes in rats and 6-9 minutes in dogs. Plasma half-life was under 30 minutes in both species. Metabolism produced six small peptide fragments; elimination was urinary and biliary [11]. The peptide's stability in gastric juice — the original premise of its discoverers — has been confirmed across many rodent protocols, where drinking-water administration produces measurable biological effects. Oral bioavailability has not been formally quantified in healthy humans. ## § 04 Where the evidence stops A 2025 systematic review in *HSS Journal* indexed thirty-six BPC-157 articles published between 1993 and 2024. Thirty-five were preclinical. One was clinical [16]. That ratio is the single most important fact on this page. The entire published human file is three small uncontrolled reports from a single investigator group between 2021 and 2025: intra-articular injection in 16 knees, intravesicular injection in 12 bladders, and a single-arm intravenous infusion in healthy volunteers [17]. None is a controlled trial. None has been replicated by an independent group. In September 2023 the U.S. Food and Drug Administration placed BPC-157 on its Category 2 list of bulk drug substances that may present significant safety risks, excluding it from 503A pharmacy compounding. The World Anti-Doping Agency added it to the Prohibited List under section S0 (Non-Approved Substances), effective 1 January 2022 [16][18]. ## § 05 Mechanism in three sentences The peptide is described as multi-pathway. Across in vivo rodent work, it acts through the VEGFR2-PI3K-Akt-eNOS axis to promote angiogenesis [4], modulates all three nitric oxide synthase isoforms in a substrate-independent fashion [7][20], upregulates the growth hormone receptor in tendon fibroblasts via JAK2 [2], shifts macrophage polarization toward the M2 anti-inflammatory phenotype, and engages the FAK-paxillin pathway in fibroblast migration and collagen organization. None of these mechanisms have been validated in controlled human trials. In vitro angiogenic assays on isolated cells are negative — the in vivo effect appears to require the wound microenvironment. ## § 06 How to read this site Six pages of substance. */research* catalogues the preclinical evidence by tissue and mechanism. */dosage* reports dose ranges in the species and route in which they were studied — no human translation, no protocols, no recommendations. */effects* summarizes the reported effects and the safety cautions the literature raises. */faq* answers the questions a careful reader brings to the literature. */references* lists every cited study with DOI and link. */about* explains what this publication is and is not. */contact* is for editorial correspondence only. This is an editorial digest of the published research — nothing is offered for sale here, no vendor is referred to, and no human dose is suggested. The publication runs no analytics, no trackers, no third-party scripts. Every page has a markdown alternate at `/path.md` for AI agents and crawlers; a curated reading list at `/llms.txt`; and a single-file concatenation at `/llms-full.txt`. All three are linked from the footer. --- A modernist reading of the published literature — not a clinical opinion. --- # BPC-157 reported effects and safety — community signals and cautions > BPC-157 reported effects: what people in research-use communities describe, the known safety cautions, and the honest state of human evidence. For research context only. Community signals from research-use settings, alongside the mechanistic safety questions the literature raises. Neither replaces a controlled trial. ## § 01 The short version BPC-157 is a research peptide, not an approved drug. The evidence behind it is overwhelmingly from rodent studies — decades of animal data converge on a picture of accelerated tissue repair, but that picture has almost never been tested in a controlled human trial. The three small human pilot reports that exist are uncontrolled, from a single investigator group, and too small to establish benefit or safety. What follows is what people in research-use communities report — clearly labeled as anecdotal, not clinical evidence — alongside the theoretical safety questions that mechanism-based reasoning and the small human file raise. Read this page alongside [the research summary](/research), which gives the full preclinical and human evidence record. ## § 02 What people report **These are community reports — anecdotal, not clinical evidence.** They describe what people say in research-use settings. They are not findings from controlled trials and cannot establish that BPC-157 caused any of the effects described. **Benefits reported** *Faster recovery from tendon, ligament and joint injuries* (very commonly reported). The most frequently cited reason people try BPC-157 in research-use communities. Accounts describe stubborn problems — tennis elbow, rotator-cuff strains, old sprains — feeling more usable, often within one to three weeks. *Less joint stiffness and pain* (frequently reported). Day-to-day joint stiffness easing and painful movements becoming easier, sometimes within one to two weeks. People describe returning to training or activity sooner than expected. *Improved digestive or gut symptoms* (frequently reported). Users report less bloating, cramping and urgency, and better tolerance of foods that previously caused discomfort, typically within the first one to two weeks. *A general sense of reduced inflammation or feeling better* (occasionally reported). A broad impression of easier movement or less systemic discomfort, which is difficult to separate from placebo. *Faster skin and wound healing* (occasionally reported). Cuts and minor wounds appearing to close faster, which users connect to the peptide's reported pro-angiogenic (new-blood-vessel-forming) effect. *Better sleep, mood or stress tolerance* (occasionally reported). Some people report steadier mood or improved sleep; commentators note this could reflect better sleep from reduced pain or gut symptoms rather than a direct brain effect. **Adverse effects reported** *Injection-site redness, stinging or a small bump* (very commonly reported). Brief stinging, redness or a small raised bump at the injection site, generally described as resolving within an hour to a day. *Nausea or mild stomach upset* (frequently reported). Mild nausea, loose stools or stomach cramping, especially in the first few days. More common with oral or sublingual products than with injections. Generally self-resolving. *Fatigue or feeling tired in the first week* (occasionally reported). Unusual tiredness during the first week of use that people say settles on its own. *Headache* (occasionally reported). Mild, transient headaches mentioned across user surveys and clinic write-ups. *Dizziness or lightheadedness, often shortly after injecting* (occasionally reported). May relate to the act of injecting or to the peptide's reported effects on blood-vessel tone and the nitric-oxide system. *Transient flushing or warmth* (occasionally reported). A wave of warmth or flushing in the face, chest or limbs within about thirty minutes of injecting, fading after the first week. Users connect it to vascular effects. *Heart palpitations or a racing feeling* (rarely reported). A small number of people mention occasional palpitations. Persistent rapid heartbeat, chest pain or marked blood-pressure changes would be reasons to stop and seek medical evaluation. ## § 03 Safety and cautions The cautions below come from three sources: the thin human evidence record, mechanistic reasoning from the animal literature, and regulatory decisions. **The human evidence is extremely thin.** Almost everything known about BPC-157 in repair contexts comes from rodent studies. As of 2025, only three small uncontrolled human pilot reports exist, and large, rigorous controlled trials are lacking [17][16]. Animal findings should not be read as proven benefits in people. The real balance of benefit and risk in humans is genuinely unknown. **Much of the foundational research comes from one group.** A large share of the BPC-157 preclinical literature was produced by a single research group and its collaborators; independent replication is limited [17]. 2025 reviewers flag this explicitly. The broad, consistent-looking animal signal has not been widely confirmed by unrelated laboratories. **BPC-157 is not an approved drug; unregulated products vary.** BPC-157 is not approved as a medicine anywhere. It is sold for laboratory research use only. Because it moves through non-regulated channels, the identity, purity and actual content of any given product are unverified outside formal studies [18][16]. **Strong pro-angiogenic activity raises a theoretical concern in cancer** (mechanistic caution, not a human finding). BPC-157's repair effects in animals are linked to angiogenesis — the formation of new blood vessels — partly through the VEGFR2 pathway. Because tumors also rely on new blood-vessel growth, there is a theoretical concern that a strongly pro-angiogenic agent could be unwelcome in someone with active or suspected cancer [18]. This has not been studied in humans. **Possible interaction with serotonin-affecting medicines** (preclinical caution). In rodent work, BPC-157 changes brain serotonin activity and has altered the course of drug-induced serotonin syndrome in rats [22][25]. There is a mechanism-based concern that combining it with serotonin-raising medicines could have unpredictable effects. This has not been studied in humans. **Growth-signaling promotion; long-term effects unknown** (mechanistic caution). In cultured tendon cells, BPC-157 increased growth-hormone-receptor signaling [2]. Any agent that nudges growth pathways carries a theoretical question about long-term or unwanted tissue effects. There are no long-term human safety data to answer it. **Banned in competitive sport.** BPC-157 is prohibited at all times by the World Anti-Doping Agency under its S0 category for non-approved substances [16][18]. Athletes subject to drug testing face potential sanctions. **Unstudied in pregnancy, breastfeeding and children.** As a tissue-growth-influencing peptide with no human safety database, it would be reasonable to avoid in these groups. No human data support use in any of these populations. --- A modernist reading of the published literature — not a clinical opinion. --- # BPC-157 research literature — mechanism, animal studies, human reports > A structured summary of the BPC-157 research literature: VEGFR2 and nitric oxide signaling, musculoskeletal models in rats and rabbits, gastrointestinal anastomoses, ischemia-reperfusion, central nervous system models, and the three published human reports. Thirty-three years of preclinical work, organised by tissue and mechanism, followed by what little exists in humans. ## § 00 The short version The BPC-157 research record is large by peptide standards and almost entirely preclinical. A 2025 systematic review in HSS Journal counted thirty-six indexed articles published between 1993 and 2024 — thirty-five were animal studies, one was clinical. The animal work covers tendon, ligament, bone, muscle, gut, peripheral nerve, spinal cord, brain and distant-organ protection, all in rodents. Mechanisms centre on angiogenesis (via the VEGFR2-Akt-eNOS pathway), nitric-oxide modulation, and growth-hormone-receptor upregulation in tendon fibroblasts. A caution: a large share of this record comes from a single research group at Zagreb; independent replication at scale has not occurred. The human file is three small uncontrolled pilot reports from that same group. No randomized controlled trial has been completed. The breadth of the animal signal and the thinness of the human record are both real, and reading this page honestly means holding both facts simultaneously. ## § 01 Mechanism BPC-157 is described as multi-pathway. The most-cited mechanism is angiogenesis through the VEGFR2-PI3K-Akt-eNOS axis. The peptide promotes formation of new vessels from existing vasculature; in vivo this presents as increased VEGF expression and increased CD34/FVIII-positive microvascular density at the injury site [4]. In vitro angiogenic assays on isolated cells are negative — the effect appears to require the wound microenvironment. A second mechanism is nitric oxide modulation. The peptide alters activity across all three nitric oxide synthase isoforms — endothelial (eNOS), neuronal (nNOS), inducible (iNOS) — and effects often persist under L-NAME inhibition or L-arginine substrate challenge. This is read as a *modulatory rather than substrate-dependent* role [7]. Hsieh et al. (2020) reported activation of the Src-Caveolin-1-eNOS pathway in rat aortic preparations, implicating BPC-157 in vasomotor tone regulation [20]. In cultured tendon fibroblasts, Chang et al. (2014) reported a dose- and time-dependent increase in growth hormone receptor mRNA and protein up to sevenfold, with co-incubation with growth hormone amplifying proliferation via JAK2 [2]. The peptide is also reported to shift macrophage polarization toward an M2 anti-inflammatory phenotype and to engage the FAK-paxillin pathway in fibroblast migration. ## § 02 Tendon, bone, muscle *Tendon.* Staresinic et al. (2003) administered 10 μg/kg or 10 ng/kg intraperitoneal to Sprague-Dawley rats after Achilles transection. Treated animals showed increased load-to-failure, superior collagen and reticulin organization, and macroscopic and microscopic restoration of tendon integrity. Parallel in vitro work reversed 4-hydroxynonenal-induced growth inhibition of cultured tendocytes [1]. Krivic et al. (2006) extended the model to tendon-to-bone detachment and reported that the peptide counteracted the negative effect of concurrent methylprednisolone, a corticosteroid known to impair tendon healing [3]. *Bone.* Sebecic et al. (1999) studied rabbit segmental bone defects. BPC-157 at 10 μg/kg, applied locally and intramuscularly, produced bony union comparable to autologous cortical bone grafting or bone-marrow application [5]. The comparison to autograft — the standard against which orthopaedic bone-graft substitutes are measured — is unusual. The model has not, to our reading, been replicated by an independent group. *Muscle.* Matek et al. (2025) reported in *Pharmaceutics* that per-oral BPC-157 in drinking water at 10 μg/kg/day or 10 ng/kg/day (0.16 μg/mL or 0.16 ng/mL) closed a surgically detached quadriceps-to-bone gap by day 21-28, restored walking pattern, reduced motor function index scores, and produced well-organized periosteum and oriented type-I collagen [14]. *Synthesis.* Vasireddi et al. (2025) in *HSS Journal* identified thirty-six BPC-157 articles between 1993 and 2024: thirty-five preclinical, one clinical. The musculoskeletal preclinical signal across tendon, ligament, muscle, and bone was characterized as broad. Human evidence was characterized as minimal [16]. ## § 03 Gastrointestinal BPC-157 was originally framed by its discoverers as a *stable gastric pentadecapeptide* with cytoprotective action across the GI tract. Sikiric et al. (2012) reviewed the colitis literature: cysteamine and vascular-occlusion-related rat colitis models showed reduced colonic ulceration, edema, and inflammatory infiltrate with BPC-157 at 10 μg/kg or 10 ng/kg [24]. A 2024 review in *Pharmaceuticals* (Bajramagic et al.) catalogued rat intestinal anastomosis studies across four segments — esophagogastric, colocolonic, jejunoileal, and ileoileal — reporting reduced leakage, increased burst pressure, less necrosis, increased epithelialization, more granulation tissue, and fewer inflammatory infiltrates with BPC-157 administration [13]. Fistula models are a recurring endpoint. Klicek et al. (2008) reported closure of colocutaneous fistulas with maintained efficacy under NOS modulation [7]. Vukusic et al. (2024) reported closure of duodenocolic fistulas with reduced adhesion and altered NOS2/COX-2/VEGFA expression [19]. Madzarac et al. (2026, online) reported tracheocutaneous fistula closure with normalization of nitric oxide and malondialdehyde levels in a *triple NO-agent* paradigm — BPC-157 either reversed L-NAME aggravation or enhanced L-arginine-mediated outcomes [23]. The single human trial in this domain is the Pliva Phase II enema program for mild-to-moderate ulcerative colitis (PL 14736). The trial is reported as completed and well tolerated; full efficacy data were never published in a peer-reviewed clinical paper, and the program was not advanced further [6]. ## § 04 Nerve, spinal cord, brain, distant organs *Peripheral nerve.* Gjurasin et al. (2010) studied transected sciatic nerve in rats and reported faster axonal regeneration, greater myelin sheath thickness, increased blood-vessel density at the repair site, and improved sciatic functional index scores with 10 μg/kg or 10 ng/kg, administered locally and systemically [8]. *Spinal cord.* Perovic et al. (2019) compressed rat sacrocaudal spinal cord and administered a single intraperitoneal injection at 10 minutes post-injury — note the dose elevation in CNS work, 200 μg/kg or 2 μg/kg — reporting clinical improvement, restored tail motor function, abolished autotomy, and resolved spasticity by day 15. Histology showed reduced vacuolization, less axonal loss, and motoneuron preservation [9]. *Brain.* Vukojevic et al. (2022) reported in a mouse closed traumatic brain injury model that BPC-157 at 10 μg/kg or 10 ng/kg reduced subarachnoid and intraventricular hemorrhage, brain lacerations, cerebral edema, and post-injury mortality across 24 hours [10]. *Distant-organ damage.* Demirtas et al. (2025) studied 45 minutes of infrarenal aortic clamping followed by 120 minutes of reperfusion in Wistar rats. 20 μg/kg intraperitoneal BPC-157 reduced histologic damage to liver, kidney, and lung, raised total antioxidant status, lowered total oxidative status, and enhanced paraoxonase-1 activity [12]. ## § 05 The three human reports McGuire et al. (2025), in *Current Reviews in Musculoskeletal Medicine*, summarized the entire published human evidence base as three reports from a single investigator group. Lee and Padgett (2021) administered intra-articular BPC-157 to the knees of 16 patients; 14 (87.5%) reported pain relief. Lee et al. (2024) administered 10 mg intravesicular BPC-157 to 12 women with interstitial cystitis previously unresponsive to pentosan polysulfate and reported 80-100% symptom resolution. Lee and Burgess (2025) administered single-arm intravenous infusion up to 20 mg in healthy volunteers and reported tolerability with clearance within 24 hours and no adverse events [17]. All three are small. All three are uncontrolled. All three are from one group. There is no published randomized controlled trial. There is no actively recruiting registered trial in the major international registries as of this writing — the only Phase I registration on ClinicalTrials.gov, NCT02637284 (PCO-02 in healthy volunteers, 2015), was cancelled in 2016 without published results. ## § 06 Reading the literature honestly Two facts have to hold simultaneously. The preclinical signal is broad, internally consistent across more than thirty years and many tissue types, with biomechanical, histologic, and molecular endpoints converging on a coherent picture of accelerated repair. And: this signal lives almost entirely in one lab's rats, has not been independently replicated at scale, and crosses into humans only through three uncontrolled case series. Neither fact disposes of the other. A 2025 *Inflammopharmacology* commentary on Sikiric's thirty-year body of work describes the peptide as a hormone-like gastro-protectant with apparently low toxicity in the doses tested, while flagging unresolved questions about structure-activity relationships and pharmacogenetics. The same reviews that catalogue the preclinical effects raise theoretical concerns: VEGFR2-mediated angiogenesis could be problematic in malignant or pre-malignant settings; proline metabolites can activate proline oxidase and generate reactive oxygen species; excessive nitric oxide production may impair drug metabolism [18]. None of this is resolved. None of it will be resolved without controlled human work. --- A modernist reading of the published literature — not a clinical opinion. --- # BPC-157 dosage in the research literature — species, route, half-life > Dose ranges, routes, and pharmacokinetics from the BPC-157 research literature, reported in the species and administration context of each study. This page does not recommend any human dose. Every value on this page belongs to the species and route in which it was administered. None of it is a recommendation. ## § 00 The short version Every dose on this page describes what was given to rodents (or, in one pharmacokinetic study, beagle dogs) in a published experiment — not a recommendation for any human. The two doses that appear most often in the rodent literature are 10 micrograms per kilogram and 10 nanograms per kilogram, given intraperitoneally or in drinking water. A formal pharmacokinetic study in rats and dogs found a plasma half-life under thirty minutes after intramuscular dosing. The only human data are three small, uncontrolled pilot reports using doses of 10 mg intravesical, single-arm intravenous infusions up to 20 mg, and intra-articular knee injections — all from one investigator group. There is no established human dose. The FDA placed BPC-157 on its Category 2 compounding list in 2023. This site reports what was studied; it does not translate animal doses to humans. ## § 01 The two recurring rodent doses Across the bulk of the Sikiric-group preclinical literature, the same paired doses recur: **10 μg/kg** and **10 ng/kg**. Both are given intraperitoneally, intragastrically, or in drinking water [1][3][4][7][8][14][19][23]. The thousand-fold separation is intentional — the low arm tests whether the effect persists at biologically negligible exposures, and in many of the published studies it does. In drinking-water protocols the in-water concentrations correspond to 0.16 μg/mL or 0.16 ng/mL, based on an assumed 12 mL/rat/day intake [14]. The drinking-water route is unusual for a peptide and is enabled by the stability that follows from three consecutive prolines at positions 3-5 of the sequence. ## § 02 Where the dose escalates Central nervous system studies use higher doses. Perovic et al. (2019) administered 200 μg/kg or 2 μg/kg intraperitoneally in a rat sacrocaudal spinal cord compression model, given as a single injection at 10 minutes post-injury [9]. Ischemia-reperfusion studies have used 20 μg/kg intraperitoneally in Wistar rats [12]. He et al. (2022) profiled pharmacokinetics in rats over 20-500 μg/kg intramuscular and in beagle dogs over 6-150 μg/kg intramuscular without observing acute toxicity in that range [11]. In cell-culture work, concentrations of 0.1-0.5 μg/mL are typical [2]. ## § 03 Pharmacokinetics He et al. (2022) is the principal pharmacokinetic source. After intramuscular dosing, bioavailability was **14-19% in rats** and **45-51% in beagle dogs**. **Tmax was approximately 3 minutes in rats and 6-9 minutes in dogs.** **Plasma half-life was under 30 minutes** in both species. Metabolism generates six small peptide fragments, with proline among the terminal residues; elimination is urinary and biliary [11]. The short plasma half-life is sometimes raised as a paradox against the relatively long-running biological effects seen in tendon, muscle, and intestinal healing studies. The literature does not fully resolve this paradox. Two hypotheses circulate: that downstream signaling effects (eNOS activation, growth hormone receptor upregulation, macrophage polarization) outlast the peptide's plasma presence; and that the metabolite fragments themselves retain some activity. Neither is established. Intramuscular bioavailability of 14-19% in rats is low for a peptide research compound; the dog value (45-51%) is substantially higher. He et al. proposed, on a rat-to-dog allometric scaling basis, an extrapolated human dose of approximately 200 μg/person/day — explicitly as an *exploratory calculation*, not a human dose recommendation [11]. This site does not endorse that extrapolation. ## § 04 Routes that have been studied In the published literature, BPC-157 has been administered: - intraperitoneally (i.p.) — the most common route in rat work - intragastrically (i.g.) by oral gavage - per-orally in drinking water — relies on stability in gastric juice - subcutaneously (s.c.) — used in some CNS and antidepressant-effect studies - intramuscularly (i.m.) — the route used in the He et al. pharmacokinetic work - topically as a 1 µg/g cream in wound-healing models - intravenously — only in the 2025 Lee & Burgess healthy-volunteer pilot, single-arm, up to 20 mg [17] - intra-articularly — only in the 2021 Lee & Padgett knee case series [17] - intravesicularly — only in the 2024 Lee et al. interstitial cystitis case series, 10 mg per session [17] The last three are the only human-administration routes in the published file. Two of them — IV and intravesicular — were used by exactly one investigator group, in uncontrolled designs, with twelve to sixteen subjects each. ## § 05 Safety in animal toxicology The 2025 Pharmaceuticals review (Jozwiak et al.) catalogues acute toxicology: no observed teratogenic, genotoxic, anaphylactic, or local toxic effects at doses up to 20 mg/kg intramuscular in Sprague-Dawley rats and 10 mg/kg intramuscular in beagle dogs [18]. These are orders of magnitude above the 10 μg/kg dose used in efficacy studies. The same review raises three theoretical safety questions that have not been addressed by controlled human work: - VEGFR2-mediated angiogenesis could be problematic in malignant or pre-malignant settings - Proline metabolites can activate proline oxidase and generate reactive oxygen species - Excessive nitric oxide production may impair hepatic drug metabolism None of these is a finding. All three are mechanistic predictions a careful reader should weigh against the absence of long-term controlled human safety data. ## § 06 What this page does not provide This page does not contain a human dose. It does not suggest a schedule, a route, or a duration. It does not refer to vendors, compounding pharmacies, or product sources. BPC-157 was placed on the FDA Category 2 list in September 2023, which excludes it from 503A pharmacy compounding for human use. It is prohibited in WADA-sanctioned competition under category S0, effective 1 January 2022 [16][18]. No regulatory authority has approved BPC-157 for any human indication. Values here describe what was studied. They do not describe what should be taken. --- A modernist reading of the published literature — not a clinical opinion. --- # BPC-157 frequently asked — research, regulatory, dosage, safety > Fifteen direct questions on BPC-157: what it is, what the studies show, the FDA and WADA position, where the human evidence sits, and how to read the literature carefully. Direct answers, each anchored to a study or a regulatory document. ## § 01 Background **What is BPC-157?** BPC-157 is a synthetic peptide of fifteen amino acids — sequence GEPPPGKPADDAGLV, molecular weight 1419.55 Da. The sequence was identified within a larger cytoprotective protein found in human gastric juice [11]. Synonyms in the literature include Pentadecapeptide BPC 157, PL 14736, PL-10, and PLD-116. **Where did it come from?** The peptide was characterized and named in the early 1990s by a research group led by Predrag Sikiric at the University of Zagreb. The Croatian pharmaceutical company Pliva later registered the molecule under the development code PL 14736 and advanced an enema formulation into Phase II trials for ulcerative colitis [6]. The program was not advanced further and the full trial data were never published in a standalone peer-reviewed paper. **Why is it called *Body Protection Compound*?** The name reflects the framing of its discoverers: a peptide that protects body tissues from injury. In the literature it is described as *cytoprotective* across the gastrointestinal mucosa, vasculature, tendon, ligament, muscle, bone, and central nervous system in rodent injury models. ## § 02 Evidence **Does it work?** In rodents, in many models, the published literature reports that it does. In humans, the published file is three uncontrolled reports from one investigator group between 2021 and 2025 [17]. Whether that constitutes *working* depends on which evidence bar a reader is applying. **How many BPC-157 studies are there?** A 2025 systematic review in *HSS Journal* indexed thirty-six articles published between 1993 and 2024. Thirty-five were preclinical. One was clinical [16]. Many more individual experiments exist across reviews and conference papers, but the count of indexed primary articles is small relative to the size of the popular conversation. **Are there human trials?** One Phase II program ran (PL 14736, Pliva, ulcerative colitis) and was not published in full or advanced [6]. One Phase I registration (NCT02637284, PCO-02 in healthy volunteers) was cancelled in 2016. Three uncontrolled case series and one IV pilot have appeared in the literature since 2021, all from one group [17]. No randomized controlled trial has been published. No registered trial is actively recruiting in the major international registries at the time of writing. **Why is most of the research in rats?** Because that is what has been done. The Sikiric group at Zagreb produced the dominant share of the preclinical record over thirty years using rat and mouse models with occasional rabbit and dog work. Replication by independent groups at the same scale has not occurred. Whether this is a feature of the peptide's chemistry or of the research economics around an unapproved compound is not something the literature settles. ## § 03 Mechanism **How is it described as working?** The most-cited mechanism is angiogenesis through the VEGFR2-PI3K-Akt-eNOS pathway, supported by increased VEGF expression and microvascular density at injury sites in vivo [4]. A second mechanism is nitric oxide modulation across all three NOS isoforms, with the peptide acting as a modulator rather than a substrate [7][20]. In tendon fibroblasts the peptide upregulates growth hormone receptor mRNA and protein up to sevenfold and amplifies proliferation in the presence of growth hormone via JAK2 [2]. **Does it act locally or systemically?** Both, depending on the study. Local injection, intra-articular injection, topical cream, and intravesicular instillation have been used in some protocols. Systemic intraperitoneal, intragastric, oral (drinking water), subcutaneous, and intramuscular routes have been used in others. Effects have been reported across all of these routes in preclinical work [11][13][14]. ## § 04 Dosing in studies **What doses are used in the research?** In most rodent work, **10 μg/kg** and **10 ng/kg** are administered intraperitoneally, intragastrically, or per-orally in drinking water [1][3][4][7][14]. CNS work uses higher doses (e.g. 200 μg/kg in spinal cord injury models [9]). The three human reports used 10 mg intravesicular [17], single-arm IV up to 20 mg [17], and intra-articular knee injections at undisclosed exact doses [17]. **What is the half-life?** Plasma half-life is under 30 minutes in both rats and dogs after intramuscular dosing, with Tmax of ~3 minutes (rat) and ~6-9 minutes (dog) [11]. **Is it stable in the stomach?** Yes — this is the *stable* in *stable gastric pentadecapeptide*. The three consecutive prolines at positions 3-5 of the sequence appear to confer resistance to gastric proteolysis, which is why drinking-water administration is a documented research route [11][14]. ## § 05 Regulation **What is the FDA's position?** In September 2023, the FDA placed BPC-157 on its Category 2 list of bulk drug substances that may present significant safety risks, effectively excluding it from 503A pharmacy compounding for human use. The agency has issued public statements identifying BPC-157 as an unapproved drug found in some wellness products [16][18]. **Is it banned by WADA?** Yes. BPC-157 was added explicitly to the WADA Prohibited List under section S0 (Non-Approved Substances) effective 1 January 2022, and has remained on subsequent annual lists. The prohibition applies in and out of competition. There is no Therapeutic Use Exemption pathway because the peptide has no approved human therapeutic indication [16][18]. **Is it a controlled substance?** Not under the U.S. Controlled Substances Act. State-level regulations on research chemicals vary. ## § 06 Safety **What does animal toxicology show?** Acute studies in Sprague-Dawley rats up to 20 mg/kg intramuscular and beagle dogs up to 10 mg/kg intramuscular reported no observed teratogenic, genotoxic, anaphylactic, or local toxic effects [18]. These doses are several orders of magnitude above the typical 10 μg/kg efficacy dose. **What are the theoretical concerns?** The 2025 *Pharmaceuticals* review (Jozwiak et al.) flags three: VEGFR2-mediated angiogenesis as a possible concern in malignant or pre-malignant settings; proline metabolites activating proline oxidase and generating reactive oxygen species; and excessive nitric oxide impairing hepatic drug metabolism [18]. These are mechanistic predictions, not findings. **Are there documented adverse events in humans?** In the three published human reports (16 + 12 + an open IV pilot), the authors reported no adverse events at the doses used [17]. Sample sizes are small. There is no published controlled long-term human safety data. There is no post-marketing surveillance — because there is no marketing. --- A modernist reading of the published literature — not a clinical opinion. --- # BPC-157 references — full citation list with DOIs > Full reference list for the BPC-157 research summary: every cited paper with authors, journal, year, DOI, and PubMed/PMC link. Twenty-four primary studies and reviews. DOIs and PubMed/PMC links for every entry. ## § 01 Reference list The full citation list appears below. Each entry is numbered to match the inline `[N]` markers used across /research, /dosage, /faq, and /index. DOI and PubMed/PMC URLs are provided for every entry. The list is also available as a structured ItemList in the page's JSON-LD. ## References [1] Staresinic M, Sebecic B, Patrlj L, Jadrijevic S, Suknaic S, Perovic D, Aralica G, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. Journal of Orthopaedic Research. 2003;21(6):976-983. https://onlinelibrary.wiley.com/doi/10.1016/S0736-0266(03)00110-4 [2] Chang CH, Tsai WC, Hsu YH, Pang JHS. Pentadecapeptide BPC 157 Enhances the Growth Hormone Receptor Expression in Tendon Fibroblasts. Molecules. 2014;19(11):19066-19077. https://pmc.ncbi.nlm.nih.gov/articles/PMC6271067/ [3] Krivic A, Anic T, Seiwerth S, Huljev D, Sikiric P. Achilles detachment in rat and stable gastric pentadecapeptide BPC 157: promoted tendon-to-bone healing and opposed corticosteroid aggravation. Journal of Orthopaedic Research. 2006;24(5):982-989. https://pubmed.ncbi.nlm.nih.gov/16583442/ [4] Brcic L, Brcic I, Staresinic M, Novinscak T, Sikiric P, Seiwerth S. Modulatory effect of gastric pentadecapeptide BPC 157 on angiogenesis in muscle and tendon healing. Journal of Physiology and Pharmacology. 2009;60 Suppl 7:191-196. https://pubmed.ncbi.nlm.nih.gov/20388964/ [5] Sebecic B, Nikolic V, Sikiric P, Seiwerth S, Sosa T, Patrlj L, et al. Osteogenic effect of a gastric pentadecapeptide, BPC-157, on the healing of segmental bone defect in rabbits. Bone. 1999;24(3):195-202. https://pubmed.ncbi.nlm.nih.gov/10071911/ [6] Sikiric P, Seiwerth S, Brcic L, et al. Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease (PL-10, PLD-116, PL 14736, Pliva, Croatia). Inflammopharmacology. 2006;14(5-6):214-221. https://pubmed.ncbi.nlm.nih.gov/17186181/ [7] Klicek R, Sever M, Radic B, Drmic D, Kocman I, Zoricic I, et al. Pentadecapeptide BPC 157, in clinical trials as a therapy for inflammatory bowel disease (PL14736), is effective in the healing of colocutaneous fistulas in rats: role of the nitric oxide-system. Journal of Pharmacological Sciences. 2008;108(1):7-17. https://pubmed.ncbi.nlm.nih.gov/18818478/ [8] Gjurasin M, Miklic P, Zupancic B, Perovic D, Zarkovic K, Brcic L, et al. Peptide therapy with pentadecapeptide BPC 157 in traumatic nerve injury. Regulatory Peptides. 2010;160(1-3):33-41. https://pubmed.ncbi.nlm.nih.gov/19903499/ [9] Perovic D, Kolenc D, Bilic V, Somun N, Drmic D, Elabjer E, et al. Stable gastric pentadecapeptide BPC 157 can improve the healing course of spinal cord injury and lead to functional recovery in rats. Journal of Orthopaedic Surgery and Research. 2019;14(1):199. https://pubmed.ncbi.nlm.nih.gov/31266512/ [10] Vukojevic J, Milavic M, Perovic D, Ilic S, Cilic AZ, Duran N, et al. Pentadecapeptide BPC 157 and the central nervous system. Neural Regeneration Research. 2022;17(3):482-487. https://pubmed.ncbi.nlm.nih.gov/34380875/ [11] He L, Feng D, Guo H, et al. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs. Frontiers in Pharmacology. 2022;13:1026182. https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2022.1026182/full [12] Demirtas H, Ozer A, Yildirim AK, Dursun AD, Sezen SC, Arslan M. Protective Effects of BPC 157 on Liver, Kidney, and Lung Distant Organ Damage in Rats with Experimental Lower-Extremity Ischemia–Reperfusion Injury. Medicina (Kaunas). 2025;61(2):291. https://pmc.ncbi.nlm.nih.gov/articles/PMC11857380/ [13] Bajramagic S, Sever M, Rasic F, Staresinic M, Skrtic A, Beketic Oreskovic L, et al. Stable Gastric Pentadecapeptide BPC 157 and Intestinal Anastomoses Therapy in Rats—A Review. Pharmaceuticals (Basel). 2024;17(8):1081. https://pmc.ncbi.nlm.nih.gov/articles/PMC11357423/ [14] Matek D, Matek I, Staresinic E, Japjec M, Bojanic I, et al. Stable Gastric Pentadecapeptide BPC 157 as Therapy After Surgical Detachment of the Quadriceps Muscle from Its Attachments for Muscle-to-Bone Reattachment in Rats. Pharmaceutics. 2025;17(1):119. https://pmc.ncbi.nlm.nih.gov/articles/PMC11768438/ [15] Lojo N, Rasic Z, Boban Blagaic A, Cesarec V, Drmic D, et al. Pentadecapeptide BPC 157 and its effects on a NSAID toxicity model: diclofenac-induced gastrointestinal, liver, and encephalopathy lesions. Life Sciences. 2011. https://www.sciencedirect.com/science/article/abs/pii/S002432051100035X [16] Vasireddi N, Hahamyan H, Salata MJ, Karns M, Calcei JG, Voos JE, Apostolakos JM. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS Journal. 2025. https://journals.sagepub.com/doi/abs/10.1177/15563316251355551 [17] McGuire FP, Martinez R, Lenz A, Skinner L, Cushman DM. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Current Reviews in Musculoskeletal Medicine. 2025;18(12):611-619. https://pmc.ncbi.nlm.nih.gov/articles/PMC12446177/ [18] Jozwiak M, Bauer M, Kamysz W, Kleczkowska P. Multifunctionality and Possible Medical Application of the BPC 157 Peptide—Literature and Patent Review. Pharmaceuticals (Basel). 2025;18(2):185. https://pmc.ncbi.nlm.nih.gov/articles/PMC11859134/ [19] Vukusic D, Zenko Sever A, Sever M, Drmic D, Milavic M, et al. Duodenocolic fistula healing by pentadecapeptide BPC 157 in rats. A cytoprotection viewpoint. Journal of Physiology and Pharmacology. 2024;75(1). https://pubmed.ncbi.nlm.nih.gov/38583442/ [20] Hsieh MJ, Liu HT, Wang CN, Huang HY, Lin Y, Ko YS, et al. Modulatory effects of BPC 157 on vasomotor tone and the activation of Src-Caveolin-1-endothelial nitric oxide synthase pathway. Scientific Reports. 2020;10(1):17078. https://www.nature.com/articles/s41598-020-74022-y [21] Sikiric P, Separovic J, Buljat G, Anic T, Stancic-Rokotov D, Mikus D, et al. The antidepressant effect of an antiulcer pentadecapeptide BPC 157 in Porsolt's test and chronic unpredictable stress in rats. Journal of Physiology, Paris. 2000;94(2):99-104. https://pubmed.ncbi.nlm.nih.gov/10791692/ [22] Boban Blagaic A, Blagaic V, Mirt M, Jelovac N, Dodig G, Rucman R, et al. Gastric pentadecapeptide BPC 157 effective against serotonin syndrome in rats. European Journal of Pharmacology. 2005;512(2-3):173-179. https://pubmed.ncbi.nlm.nih.gov/15840402/ [23] Madzarac G, Becejac T, Penovic T, et al. Tracheocutaneous Fistula Resolved by Pentadecapeptide BPC 157 Therapy Through the NO-System—Triple NO-Agent Approach in Rats. Pharmaceuticals (Basel). 2026;19(1):145. https://pmc.ncbi.nlm.nih.gov/articles/PMC12844668/ [24] Sikiric P, Seiwerth S, Brcic L, Sever M, Klicek R, Radic B, et al. Focus on Ulcerative Colitis: Stable Gastric Pentadecapeptide BPC 157. Current Medicinal Chemistry. 2012;19(1):126-132. https://www.ingentaconnect.com/content/ben/cmc/2012/00000019/00000001/art00012 [25] Tohyama Y, Sikiric P, Diksic M. Effects of pentadecapeptide BPC157 on regional serotonin synthesis in the rat brain: alpha-methyltryptophan autoradiographic measurements. Life Sciences. 2004;76(4):345-357. https://pubmed.ncbi.nlm.nih.gov/15531385/ --- A modernist reading of the published literature — not a clinical opinion. --- # About BPC-157 Dr. — editorial standards and intent > BPC-157 Dr. is an independent research-summary publication. It does not operate a clinic, prescribe medication, dispense product, or recommend doses. Editorial standards and disclaimers. What this publication is, what it is not, and how it is sourced. ## § 01 What this site is *BPC-157 Dr.* is an independent research-summary publication. Its purpose is to make the published BPC-157 literature legible to a careful reader — researchers, clinicians who encounter questions from patients, journalists, athletes navigating WADA rules, and lay readers trying to understand what is actually known about a peptide that the open internet describes with varying levels of accuracy. The publication is structured around six pages: an overview (this page is page five), a research summary indexed by tissue and mechanism, a dosage page that reports dose ranges in the species in which they were studied, a frequently-asked-questions page, a full reference list with DOIs, and a contact page. The word *Dr.* in the domain reflects the publication's voice — a single editor's reading of the field, set in a clean grid, like a one-physician letterhead — not a clinical service of any kind. ## § 02 What this site is not This site does not operate a clinic. It employs no clinicians. It does not prescribe medication, hand out any product, recommend doses, or refer readers to vendors. It is not affiliated with any pharmacy, supplement company, telehealth service, or peptide retailer. It is an editorial digest, not a storefront — nothing on it is offered for sale. It does not provide medical advice. It does not provide a protocol. It does not extrapolate a 10 μg/kg dose in a rat to any human dose under any condition. It is not a restoration of any previous owner of the domain. It is a new editorial publication at this address. ## § 03 Editorial standards Every quantitative claim on the site cites a published study with DOI and PubMed/PMC URL. Dose values are reported in the species and route in which they were administered. Mechanisms are described as *reported* or *studied* rather than as established fact when the underlying evidence is preclinical and unreplicated. Where the evidence base is thin, the site says so. The single most important fact on the site is that thirty-five of thirty-six BPC-157 articles in the 2025 *HSS Journal* systematic review were preclinical [16]. That ratio is repeated wherever a reader might mistake the breadth of the rodent record for clinical validation. The site does not mention competitor product brand names. It does not link to vendors. It does not run trackers, pixels, or analytics. It does not collect personal data. ## § 04 Sources and citations Primary sources are PubMed, PubMed Central, journal websites, and ClinicalTrials.gov. Regulatory positions are taken from FDA and WADA official documents. Reviews and systematic reviews are used to triangulate primary findings. The full reference list appears on /references. Each citation links to the DOI or to the open-access PMC version when one is available. --- A modernist reading of the published literature — not a clinical opinion. --- # Contact — BPC-157 Dr. > Editorial contact for BPC-157 Dr. — corrections, citation requests, and editorial correspondence only. This is not a medical service. Corrections and citation requests are welcome. Medical questions are not. ## § 01 When to write Write to us if: - You spot a factual error or a misattributed citation. Specify the page and the paragraph; quote the sentence; cite the source we should be using instead. - You are an author whose paper we have cited and want the entry corrected, updated, or removed. - You are a journalist looking for sources on a BPC-157 story and want a reading list. - You are a research group with a recent (2024+) publication we should know about; please link a DOI. ## § 02 When not to write Do not write to us if: - You are looking for a doctor, a clinic, or a prescription. We are none of those things. - You want to know what to take, what dose, what route, or what schedule. We do not give that information to anyone under any condition. - You are a vendor, telehealth platform, peptide reseller, or affiliate. We do not partner, link, or refer. - You are looking for medical advice. We do not provide it. Speak with a licensed clinician in your jurisdiction. ## § 03 Contact form Editorial contact is available via the form below. Messages are read but responses are not guaranteed. Please do not send personal health information. --- A modernist reading of the published literature — not a clinical opinion.